At least 7 (seven) members of the Panel on COVID-19 Treatment Guidelines have not disclosed their financial ties to Gilead Sciences (ticker GILD), the patents owner and manufacturer of remdesivir. Remdesivir is being tested under auspices of WHO for treatment of COVID-19. Currently, COVID-19 is treated by hydroxychloroquine (HCQ) with or without azithromycin (AZ).
Nine other members of the Panel have disclosed such ties to Gilead. A number of other Panel members appear to have links to Gilead that require no disclosure. Together, Gilead-linked individuals were a majority on the Panel.
This might explain why the Panel recommended against HCQ+AZ combination, refused to recommend HCQ (“insufficient clinical data to recommend either for or against”) and raised fear, uncertainty, and doubt (FUD) about it. The Panel gave the same grade (but without FUD) to remdesivir, although no clinical data for its use for COVID-19 existed at all.
The list of the Panel members who have not disclosed their financial ties to Gilead. Notice that this is not accusation against theses individuals. Somebody set the reporting period to mere 11 months (May 1, 2019 to March 31, 2020) and excluded the last three weeks. The Guidelines were published on April 21.
| Name | Financial Disclosure | Not Disclosed | |
| Company | Relationship | ||
| John T. Brooks | None | N/A | Done HIV Conferences with Gilead Sciences (2018)
https://ceitraining.org/courses/course_detail.cfm?mediaID=687 |
| Ann C. Collier | None | N/A | Past research support from Gilead (reported in 2013)
https://journals.plos.org/plosone/article/authors?id=10.1371/journal.pone.0065306 |
| Roy M. Gulick | None | N/A | Currently delivers lectures, funded with grants from Gilead
https://www.prn.org/index.php/management/article/update_from_ias_amsterdam_part_1 |
| Jeffrey L. Lennox | None | N/A | Gilead Advisory Board, 2019
https://aidsinfo.nih.gov/contentfiles/lvguidelines/glchunk/glchunk_274.pdf |
| Henry Masur | None | N/A | Gilead funded his research and conference(s), 2018 |
| Nitin Seam | None | N/A | Web Editorial Committee Chair with American Thoracic Society; Gilead is a Patron (2018)
https://www.thoracic.org/about/resources/ats-annual-report-2018.pdf |
| Phyllis Tien | None | N/A | Research Grants by Gilead (2018)
https://rsna2018.rsna.org/program/details/?publicid=SSC10-09 Please let me know if you find any error in this table or accompanying description. If you are a person in the left column, I will correct the error or publish your reply, or both. You can contact me by making a comment below (which will not be automatically published), or by email contact@defyccc.com. P.S. Do NOT delete the linked pages. First, destruction of evidence is a crime. Second, do you really think that your website and the Web Archive are the only places where their copies exist? |
via Science Defies Politics
April 27, 2020 at 06:20AM
Iowa Climate Science Education 
This is Roy Gulick, MD from Weill Cornell. Your statement above about me is incorrect — I never participated in a Gilead Advisory Board in 2019. I have not participated in ANY pharma advisory boards for 7 years. Please correct.
Roy Gulick
LikeLike